TScan Therapeutics is developing TSC-101 and multiplex TCR-Ts for cancer treatment. See why TCRX stock holds potential with ...

TEVIMBRA is a uniquely designed humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is ...

New indication based on results from a global Phase 3 trial demonstrating significantly improved overall survival benefit for PD-L1 positive patients treated with TEVIMBRA in combination with chemothe ...

On World Rare Disease Day, Apollo Hospital Navi Mumbai highlighted a rare medical success story, treating a four-year-old ...

In many high-income countries, advanced therapies such as exchange blood transfusion (ExBT) and haematopoietic stem cell transplant (HSCT) are routine, leading to better outcomes for patients. However ...

Methods: Diagnoses of HS were confirmed using immunohistochemistry, with markers such as CD68 and lysozyme. Treatment primarily involved anthracycline-based chemotherapy with autologous hematopoietic ...

3. 已证实和可能的IFD风险因素 allo-HSCT患者IFD的独立危险因素包括疾病处于晚期（危险比[HR]=2.55；95%置信区间[CI]：1.58-4.12 P<0.001）、绝对中性粒细胞计数(ANC)移植（≤28天）（HR=0.37；95% CI：0.15-0.92 P=0.032）、血小板(PLT)移植（≤28天）（HR=0.41；95% CI：0.27 -0.62 P<0.001 ...

AlloHeme test accurately predicts relapse post-allo-HSCT in AML and MDS, with a median lead time of 36 days. The ACROBAT study involved 287 patients, showing significant predictive value of ...

Later that night, PLT posted, “We at Portsmouth Little Theatre would like to thank the community for the outpouring of concern for our injured actor. Our patrons have been so thoughtful and ...

INAB READ THE FULL INAB RESEARCH REPORT IN8bio, Inc (NASDAQ:INAB) updates survival data for its INB-100 trial in a February 11th press release in preparation for presentation of data at the ...